Evidence map›Paper›PMID 27054339›Full record

ArticleCell death & disease2016

The cytoskeleton adaptor protein ankyrin-1 is upregulated by p53 following DNA damage and alters cell migration.

A E Hall, W-T Lu, J D Godfrey, A V Antonov, C Paicu, S Moxon, T Dalmay, A Wilczynska, P A J Muller, M Bushell

Open access · goldAbstract read
In one paragraph

Article in Cell death & disease, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
2.0field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 44 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Observational
  7. Review
  8. Article
  9. Review
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 1 country.

A E HallMedical Research Council (MRC), Toxicology Unit, Leicester, UK.
W-T LuMedical Research Council (MRC), Toxicology Unit, Leicester, UK.
J D GodfreyMedical Research Council (MRC), Toxicology Unit, Leicester, UK.
A V AntonovMedical Research Council (MRC), Toxicology Unit, Leicester, UK.
C PaicuThe Genome Analysis Centre, Norwich, UK.
S MoxonThe Genome Analysis Centre, Norwich, UK.
T DalmaySchool of Biological Sciences, University of East Anglia, Norwich, UK.
A WilczynskaMedical Research Council (MRC), Toxicology Unit, Leicester, UK.
P A J MullerMedical Research Council (MRC), Toxicology Unit, Leicester, UK.
M BushellMedical Research Council (MRC), Toxicology Unit, Leicester, UK.
Medical Research Council · GBMRC Toxicology Unit · GBUniversity of East Anglia · GBEarlham Institute · GB

Funding

Medical Research Council MC_EX_G0902052Medical Research Council MC_UP_1203/3Medical Research Council MC_UP_A600_1024
6 · The paper itself

Abstract

The integrity of the genome is maintained by a host of surveillance and repair mechanisms that are pivotal for cellular function. The tumour suppressor protein p53 is a major component of the DNA damage response pathway and plays a vital role in the maintenance of cell-cycle checkpoints. Here we show that a microRNA, miR-486, and its host gene ankyrin-1 (ANK1) are induced by p53 following DNA damage. Strikingly, the cytoskeleton adaptor protein ankyrin-1 was induced over 80-fold following DNA damage. ANK1 is upregulated in response to a variety of DNA damage agents in a range of cell types. We demonstrate that miR-486-5p is involved in controlling G1/S transition following DNA damage, whereas the induction of the ankyrin-1 protein alters the structure of the actin cytoskeleton and sustains limited cell migration during DNA damage. Importantly, we found that higher ANK1 expression correlates with decreased survival in cancer patients. Thus, these observations highlight ANK1 as an important effector downstream of the p53 pathway.

Indexed as

DNA DamageActin CytoskeletonAnkyrinsAntibiotics, AntineoplasticBlotting, WesternBreast NeoplasmsCell LineCell MovementDNA RepairDoxorubicinFemaleHumansMicroRNAsMicroscopy, FluorescenceProtein IsoformsRNA InterferenceANK1 protein, humanAnkyrinsAntibiotics, AntineoplasticDoxorubicinMicroRNAsMIRN486 microRNA, humanProtein IsoformsRNA, MessengerRNA, Small InterferingTumor Suppressor Protein p53

Identifiers

PMID27054339
PMCPMC4855670
OpenAlexW2324410559

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.